EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudie

Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial

Alex H Gifford, Katherine Odem-Davis, Margaret Kloster, Brian P O'Sullivan, Gregory J Omlor, Susan L Millard, John P Clancy, Gregory S Sawicki, Kristin Riekert, Nicole Mayer-Hamblett, David P Nichols, SIMPLIFY Study Group

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2024.08.008 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Alex H Gifford und 11 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Cleveland Medical Center, Cleveland, OH, USA; University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH, USA. E…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Self Report, Deoxyribonuclease I. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Highly effective CFTR modulator therapy (HEMT) has improved the health of many people with cystic fibrosis (pwCF), offering opportunities to discontinue burdensome therapies. SIMPLIFY included randomized, controlled trials that confirmed non-inferiority of discontinuing versus continuing dornase alfa (DA) or hypertonic saline (HS) for 6 weeks in pwCF on HEMT. In this study of post-trial treatment use by SIMPLIFY participants, we hypothesized that randomization to discontinue DA or HS during the trial would be associated with a higher likelihood of non-use of each medication during follow-up. METHODS: We electronically surveyed SIMPLIFY participants every 4 weeks for 24 weeks after trial completion but before the main trial results were publicly disclosed. We asked them how often they used medications during the previous week. We estimated covariate-adjusted odds ratios (ORs) of DA or HS non-use by logistic regression with generalized estimating equations. RESULTS: After exclusions mostly due to lack of any surveys, 472 participants were included in the analysis population, 181 from the HS trial and 291 from the DA trial. Approximately half of the analysis population completed all six surveys. At every month of follow-up in both trials, the percentage of individuals reporting non-use of DA or HS during the previous week was greater among those randomized to discontinue therapy. Among participants with responses at 24 weeks, 30/122 (24.6 %) in the HS trial and 79/222 (35.6 %) in the DA trial reported non-use of the respective study medication. After adjusting for covariates, participants randomized to discontinue DA were 8.7-times (95 % CI: 4.3-17.7) more likely to not use DA during follow-up than those randomized to continue DA, and participants randomized to discontinue HS were 5.2-times (95 % CI: 2.1-12.8) more likely to not use HS during follow-up compared to those randomized to continue. CONCLUSIONS: In healthy pwCF on ETI, randomization to discontinue DA or HS during SIMPLIFY was associated with greater odds of not using each medication after the trial compared to randomization to continue. These findings suggest that participation in a treatment discontinuation trial can influence participants' post-trial treatment decisions. This possibility may be relevant during discussions about research participation and clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisSelf ReportDeoxyribonuclease IHumansFemaleMaleAdultFollow-Up StudiesSaline Solution, Hypertonic

Stichwörter der Autor:innen

Cftr modulatorsCystic fibrosisDornase alfaFollow-upHypertonic salineSimplificationTreatment discontinuation

Substanzen

Deoxyribonuclease ISaline Solution, Hypertonic

Autor:innen und Institutionen

  • University Hospitals Cleveland Medical Center, Cleveland, OH, USA; University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH, USA. Electronic address: Alex.Gifford@UHhospitals.org.
  • Seattle Children's Research Institute, Seattle, WA, USA.
  • Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • Northeast Ohio Medical University, Rootstown, OH, USA.
  • Michigan State University, East Lansing, MI, USA.
  • Cystic Fibrosis Foundation, Bethesda, MD, USA.

Förderung

  • Cystic Fibrosis Foundation

Zitieren

APA

Gifford, A. H., Odem-Davis, K., Kloster, M., O'Sullivan, B. P., Omlor, G. J., Millard, S. L., Clancy, J. P., Sawicki, G. S., Riekert, K., Mayer-Hamblett, N., Nichols, D. P., & SIMPLIFY Study Group (2025). Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.08.008

Vancouver

Gifford AH, Odem-Davis K, Kloster M, O'Sullivan BP, Omlor GJ, Millard SL, et al. Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2024.08.008

BibTeX
@article{Gifford2025,
  author = {Gifford, Alex H and Odem-Davis, Katherine and Kloster, Margaret and O'Sullivan, Brian P and Omlor, Gregory J and Millard, Susan L and Clancy, John P and Sawicki, Gregory S and Riekert, Kristin and Mayer-Hamblett, Nicole and Nichols, David P and SIMPLIFY Study Group, SIMPLIFY Study Group},
  title = {Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2024.08.008}
}
Kostenlos starten →